FDA grants accelerated approval to J&J's Rybrevant for recurrent head and neck cancer

The U.S. Food and Drug Administration has issued an accelerated approval for Johnson & Johnson's antibody-drug conjugate Rybrevant targeting head and neck cancers that have returned after prior chemotherapy and immunotherapy.

The decision expands Rybrevant's approved indications beyond its existing use in lung cancer, offering a new therapeutic option for patients with limited treatment alternatives.

This marks the first FDA approval in this disease area for J&J in a decade, highlighting the company's continued focus on oncology innovations.